Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of SHR3680 in localized high-risk or locally advanced prostate cancer suitable for radical prostatectomy
CTR20211508Phase 3Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rezvilutamide in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Nov 2021; status: terminated.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20211508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211508.